CADTH Canadian drug expert committee recommendation: Doravirine (Pifeltro -- Merck Canada Inc.) indication: in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine (DOR)
The CADTH Canadian Drug Expert Committee (CDEC) recommends that DOR be reimbursed for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to DOR.
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
May 16, 2019, 2019
|
| Edition: | Final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that DOR be reimbursed for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to DOR. |
|---|---|
| Physical Description: | 1 PDF file (8 pages) |